Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

X Technologies gets FDA nod for pivotal trial:

This article was originally published in Clinica

Executive Summary

The US FDA has given X Technologies the go-ahead to begin a pivotal clinical study of its FX miniRAIL coronary dilatation catheter. The device, which will be assessed at nine centres in the US and Europe, is a low profile, 6F compatible system that integrates two flexible stainless steel wires adjacent to the dilatation balloon. These wires focus the balloon's dilatation force to create two longitudinal expansion planes in the coronary plaque and stabilise the balloon across the target lesion. The Tustin, California firm is currently launching the product in Europe.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel